SGLT2i, Pioglitazone, and Ketone Production in T2D
Status:
RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
Phase:
PHASE1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)